Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives ; volume:12 ; number:1 ; day:29 ; month:10 ; year:2019 ; pages:1-26 ; date:12.2019
Journal of hematology & oncology ; 12, Heft 1 (29.10.2019), 1-26, 12.2019
- Creator
-
Krasniqi, E.
Barchiesi, G.
Pizzuti, L.
Mazzotta, M.
Venuti, A.
Maugeri-Saccà, M.
Sanguineti, G.
Massimiani, G.
Sergi, D.
Carpano, S.
Marchetti, P.
Tomao, S.
Gamucci, T.
De Maria, R.
Tomao, F.
Natoli, C.
Tinari, N.
Ciliberto, G.
Barba, M.
Vici, P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-019-0798-2
- URN
-
urn:nbn:de:101:1-2020021901050175785215
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Krasniqi, E.
- Barchiesi, G.
- Pizzuti, L.
- Mazzotta, M.
- Venuti, A.
- Maugeri-Saccà, M.
- Sanguineti, G.
- Massimiani, G.
- Sergi, D.
- Carpano, S.
- Marchetti, P.
- Tomao, S.
- Gamucci, T.
- De Maria, R.
- Tomao, F.
- Natoli, C.
- Tinari, N.
- Ciliberto, G.
- Barba, M.
- Vici, P.
- SpringerLink (Online service)
Other Objects (12)
Is there a role for immunotherapy in HER2-positive breast cancer?
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
Is there a role for immunotherapy in HER2-positive breast cancer?
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
Is there a role for immunotherapy in HER2-positive breast cancer?
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer